Project Grant R01CA284012
Award Date 5/1/24
Completion Date 4/30/29
Dollars Obligated $378K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Portland, OR 97239, USA
Similar Awards
- This federal Project Grant award from the U.S. Department of Health and Human Services' National Cancer Institute provides $547,519 to Oregon Health & Science University (OHSU) to leverage biologically-specific PET/MRI monitoring and therapeutic modulation of the hypoxic glioblastoma tumor immune microenvironment (TIME) in order to improve outcomes for patients with glioblastoma, an aggressive form of brain cancer. The key objectives are to: 1) Define a biologically-specific imaging...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $546,308 to the University of California, San Diego under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) beginning August 1, 2025, and concluding July 31, 2030. This Project Grant supports hypothesis-driven, mechanistic research to establish the functional role of tumor neoantigen-specific T cells in pediatric brain tumors (PBTs). The research builds on preliminary findings indicating that...
- Federal Grant Award Summary Oregon Health & Science University received a $356,850 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective April 1, 2026 through March 31, 2031. The award supports research to develop and evaluate improved cancer treatment methods through the discovery, development, and clinical testing of novel therapeutic approaches. Specifically, the research targets Y-Box Binding Protein 1 (YB-1)...
- Federal Grant Award Summary The National Cancer Institute awarded Fred Hutchinson Cancer Center a $621,406 Project Grant under the 21st Century Cures Act – Beau Biden Cancer Moonshot program (CFDA 93.353) on August 1, 2025, for the PROACT study: Promoting Follow-up of Abnormal Colorectal Cancer Screening Tests through Multilevel Interventions. The project, which extends through July 31, 2030, will evaluate a multilevel intervention designed to improve follow-up colonoscopy completion rates among...
- Federal Grant Award Summary Oregon Health & Science University received a $625,179 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded on March 26, 2026, with completion targeted for February 28, 2031. The award funds research aimed at developing direct and indirect targeting strategies of the MCL1 (myeloid cell leukemia-1) protein to improve therapeutic outcomes for osteosarcoma patients with lung metastasis. The...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Beckman Research Institute of the City of Hope a $517,090 Project Grant under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, to investigate the role and biological function of a novel signature gene designated AL021978.1 (A978) in Philadelphia chromosome (PH)-positive and PH-like B-cell acute lymphoblastic leukemia (B-ALL). The research aims to address high-risk leukemia subtypes with survival...
- Federal Project Grant Award Summary The National Cancer Institute awarded Oregon Health & Science University (OHSU) a Project Grant totaling $521,002 under the Cancer Biology Research program (CFDA 93.396) on March 26, 2026, with a completion date of February 28, 2031. This award funds the development and application of a microphysiological bone metastasis-on-a-chip platform designed to advance understanding of prostate cancer metastasis to bone tissue. The research deliverables include an...
- Federal Project Grant Award Summary The National Cancer Institute's Cancer Biology Research program (CFDA 93.396) awarded Columbia University's Health Sciences Division a $501,422 Project Grant effective May 1, 2026, through April 30, 2031, to advance novel synthetic lethal (SL) therapeutic targets in cancer. The research focuses on validating the PELOTA (PELO) and HBS1-like translational GTPase (HBS1L) ribosome rescue complex as a synthetic lethal target for two distinct cancer subtypes:...
- Federal Grant Award Summary Oregon Health & Science University (OHSU) received a $109,076 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective January 16, 2026, with an ultimate completion date of July 15, 2029. The grant supports biomedical research training and investigator development in cancer research aligned with the National Cancer Program's strategic priorities. OHSU will conduct research investigating the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Ohio State University a $449,222 Project Grant effective August 20, 2025, through July 31, 2030, under the Cancer Treatment Research program (CFDA 93.395). This award funds research to elucidate the cellular and molecular mechanisms by which PD-1H (Programmed Death-1 Homolog, also known as VISTA) mediates immune suppression in acute myeloid leukemia (AML) and to evaluate its potential as a therapeutic target. The...